Parathyroid hormone
- Generic Name
- Parathyroid hormone
- Brand Names
- Natpara, Natpar
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9002-64-6
- Unique Ingredient Identifier
- N19A0T0E5J
- Background
Parathyroid hormone (PTH) is a single-chain polypeptide composed of 84 amino acids. Available as Preotact, it is an identical form of human recombinant hormome which produced as a fusion protein undergoeing post-translational processing involving the cleavage of the OmpA leader sequence, leaving the mature protein as a single-chain 84 amino-acids polypeptide (9.4 kDa).
Preotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures and is marketed in Europe by Nycomed. Preos is a registered trade mark owned by NPS Pharmaceuticals, Inc. The name Preos and the New Drug Application is pending approval by the U.S. Food and Drug Administration (FDA).
- Indication
For use/treatment in osteoporosis.
- Associated Conditions
- Hypocalcemia, Hypoparathyroidism
- Associated Therapies
- -
YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States
Ascendis Pharma announces U.S. commercial availability of YORVIPATH, the first FDA-approved treatment for hypoparathyroidism in adults. YORVIPATH, a once-daily prodrug of parathyroid hormone, aims to provide continuous exposure to active PTH. Ascendis commits to ensuring affordable access through a dedicated support program.
Advances in calcium-sensing receptor modulation: biased signaling and therapeutic potential
Liu et al. discovered new PAMs of CaSR with high affinity and biased signaling, showing less hypocalcemia than FDA-approved calcimimetics. These PAMs may overcome inhibitory effects of high phosphate levels and have potential therapeutic applications in various conditions, including cardiovascular diseases, bone regeneration, and inflammatory diseases.
2024: A breakthrough year for hypoparathyroidism treatment
Yorvipath, the first hormone treatment for hypoparathyroidism, received FDA approval in August. The drug, developed by Ascendis Pharma, replaces missing PTH to restore calcium levels. Patient testimonials highlight significant improvements in quality of life. Additionally, MBX Biosciences and Septerna Therapeutics have made strides with their respective treatments, MBX 2109 and SEP-786, aiming to address the condition's challenges. AstraZeneca's acquisition of Amolyt Pharma for $800 million underscores the growing interest in hypoparathyroidism treatments.
Ascendis Pharma Reports Third Quarter 2024 Financial Results
Ascendis Pharma reports Q3 2024 financials: YORVIPATH U.S. launch in mid-January 2025, Q3 revenue €8.5 million ex-U.S.; TransCon CNP NDA submission planned for Q1 2025, MAA for Q3 2025; SKYTROFA Q3 revenue €47.2 million; full-year 2024 SKYTROFA revenue expected €200-€220 million; operating expenses ~€600 million; Novo Nordisk collaboration for metabolic and cardiovascular diseases; Q3 total revenue €57.8 million; R&D costs €73.5 million; SG&A expenses €69.8 million; net loss €99.2 million.
New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH
3-year results from Ascendis Pharma's Phase 2 PaTH Forward Trial show long-term treatment with TransCon™ PTH (palopegteriparatide) normalized bone remodeling in hypoparathyroidism patients, promoting skeletal health parameters similar to parathyroid sufficiency.
New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated
Ascendis Pharma's 3-year Phase 2 PaTH Forward Trial results show long-term TransCon™ PTH treatment normalized bone remodeling in hypoparathyroidism patients, presented by Dr. Mishaela Rubin at ASBMR 2024.
Ascendis Pharma A/S American Depositary Shares
Ascendis Pharma A/S (ASND) is a biotech company using TransCon technology to develop prodrug therapies, focusing on North America, China, and Europe. Key products include SKYTROFA and YORVIPATH. In 2023, revenue grew to €266.7M, driven by SKYTROFA and an upfront payment. Ascendis aims to launch TransCon PTH in the U.S. in 2024 and achieve operating cash flow breakeven. Vision 2030 includes blockbuster status for three Endocrinology Rare Disease products.
3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders
Bicara Therapeutics raised $315 million in IPO to fund a pivotal study for its head and neck cancer therapy, ficerafusp alfa, which targets EGFR and TGF-beta signaling. The drug, combined with Keytruda, showed a 54% overall response rate in advanced HNSCC patients, with 64% in HPV-negative cases. A Phase 2/3 trial is planned for 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath